Sugi Predict

Sugi Predict / Compounds / SCHEMBL1711751

SCHEMBL1711751

SCHEMBL1711751

O=[N+]([O-])c1cnccc1C1=C[C@@H](O)C[C@@H](C(F)(F)F)C1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ALDH1A1 P00352 4/20 0.33
▸ HTT P42858 3/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PIM1 P11309 2/20 0.33
▸ PIM3 Q86V86 2/20 0.33
▸ PIM2 Q9P1W9 2/20 0.33
▸ MAPT P10636 4/20 0.32
▸ POLB P06746 1/20 0.31
▸ HIPK2 Q9H2X6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711754 1.00 MEN1 (0.35) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL1711755 1.00 MEN1 (0.35) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL18427343 0.86 MEN1 (0.35) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL2832661 0.82 PIM1 (0.44) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL1711410 0.82 PIM1 (0.44) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL2832662 0.82 PIM1 (0.44) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL18700540 0.82 PIM1 (0.44) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL18427344 0.81 MEN1 (0.32) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL13455455 0.81 MEN1 (0.32) MEN1KMT2AALDH1A1HTTRAB9A
SCHEMBL19099780 0.79 MEN1 (0.39) MEN1KMT2AALDH1A1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000507-B2 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2018-06-19 — — US disclosed
US-10000507-B2 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2018-06-19 — — US disclosed
US-20170190716-A1 FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2017-07-06 — — US disclosed
US-20170190716-A1 FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2017-07-06 — — US disclosed
US-9556197-B2 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2017-01-31 — — US disclosed
US-9556197-B2 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2017-01-31 — — US disclosed
US-20150315150-A1 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2015-11-05 — — US disclosed
US-20150315150-A1 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2015-11-05 — — US disclosed
EP-2344474-B1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-09-23 — — EP disclosed
US-9079889-B2 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2015-07-14 — — US disclosed
US-8329732-B2 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-12-11 — — US disclosed
US-8329732-B2 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-12-11 — — US disclosed
US-8329732-B2 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2012-12-11 — — US disclosed
US-20120134987-A1 KINASE INHIBITORS AND METHODS OF THEIR USE BURGER MATTHEW T (US) 2012-05-31 — — US disclosed
US-20120134987-A1 KINASE INHIBITORS AND METHODS OF THEIR USE BURGER MATTHEW T (US) 2012-05-31 — — US disclosed
EP-2344474-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS Novartis AG (CH) 2011-07-20 — — EP disclosed
WO-2010026124-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 — — WO disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190716-A1 FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 MEN1 3183/4885KMT2A 721/4885ALDH1A1 2130/4885
US-20120134987-A1 KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MEN1 2942/4885KMT2A 655/4885ALDH1A1 2467/4885
US-20100056576-A1 Kinase inhibitors and methods of their use PIM1, PIM2, PIM3 MEN1 2942/4885KMT2A 655/4885ALDH1A1 2467/4885
US-20150315150-A1 KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MEN1 2942/4885KMT2A 655/4885ALDH1A1 2467/4885
US-10000507-B2 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors PIM1, PIM2, PIM3 MEN1 3183/4885KMT2A 721/4885ALDH1A1 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.